SCHEMBL4687342

SCHEMBL4687342

[CH2]CCc1ccccc1NC(=O)NC1CCCCC1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.73
SMN1; SMN2 Q16637 3/20 0.68
MEN1 O00255 1/20 0.68
HTT P42858 1/20 0.68
RAB9A P51151 3/20 0.60
NPC1 O15118 2/20 0.60
EPHX1 P07099 2/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 1/20 0.57
KDM4E B2RXH2 5/20 0.55
EPHX2 P34913 2/20 0.55
ALDH1A1 P00352 3/20 0.53
MAPT P10636 1/20 0.53
MAPK1 P28482 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TSHR P16473 1/20 0.52
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693185 0.89 KMT2A (0.77) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL2750677 0.83 KMT2A (0.97) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL6439308 0.82 KMT2A (1.00) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL21504906 0.81 KMT2A (0.73) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL9162046 0.78 KMT2A (0.65) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL4688109 0.78 EPHX2 (0.57) KMT2ASMN1; SMN2MEN1RAB9ANPC1
SCHEMBL4693601 0.76 ALDH1A1 (0.66) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL8803651 0.76 KMT2A (0.61) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL8804783 0.76 KMT2A (0.61) KMT2ASMN1; SMN2MEN1HTTRAB9A
SCHEMBL8805456 0.76 KMT2A (0.61) KMT2ASMN1; SMN2MEN1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443046-B1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME KYORIN SEIYAKU KK (JP) 2008-12-17 EP disclosed
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. 2008-08-14 US disclosed
US-7375115-B2 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1443046-A1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same CYP4F2, CYP1A2, CYP4B1 KMT2A 3378/4885SMN1; SMN2 4591/4885MEN1 1716/4885
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same OPRM1, OPRD1, HRH4 KMT2A 2005/4885SMN1; SMN2 3652/4885MEN1 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.